Sodium arsenite disturbs mitosis and induces chromosome loss in human fibroblasts.
Arsenite, a unique human carcinogen, induces many types of cytogenetic alterations, such as sister chromatid exchanges, chromosome aberrations, and endoreduplication in a variety of in vivo and in vitro systems. Cytogenetic alterations are frequently associated with cancer development. The purpose of this study was to explore how arsenite induces cytogenetic alterations in human skin fibroblasts (HFW). The present results show that treatment of G2-enriched HFW cells with 5 microM arsenite results in significant delay of cell cycle progression, accumulation of mitotic cells, and prolongation of mitosis. Arsenite-induced G2 and mitotic delay are accompanied by accumulation of cyclin B1 and hyperphosphorylation of cdc2 and Mos proteins. In addition to mitotic delay and prolongation, arsenite treatment also induced out-of-phase centromere separation and alterations of chromosome segregation, such as the appearance of c-metaphase, ball-metaphase, and lagged chromosomes. Unlike spindle poisons, arsenite at the dose range used did not inhibit the spindle fiber formation but conceivably deranges the spindle apparatus. By analyzing the karyotype of established subclones surviving arsenite injury, 18% (8 of 44) showed one chromosome loss, whereas all 26 subclones derived from the untreated cultures were diploid. Furthermore, most arsenite-treated clones manifest prolonged life span (86 +/- 18 population doublings) as compared to those derived from the untreated cultures (44 +/- 11 population doublings). Unfortunately, none became immortal. Collectively, treatment of the G2-enriched HFW cells with arsenite can disturb the mitotic events and subsequently induce chromosome loss.
Yih
L H
LH
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Republic of China.
Ho
I C
IC
Lee
T C
TC
D018053:Arsenites / Q000494:pharmacology*; D016203:CDC2 Protein Kinase / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D019926:Cyclin B / Q000378:metabolism; D056744:Cyclin B1; D005347:Fibroblasts / Q000187:drug effects; D016195:G2 Phase / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007621:Karyotyping; D008938:Mitosis / Q000187:drug effects* / Q000235:genetics; D017232:Oncogene Proteins v-mos / Q000378:metabolism; D010766:Phosphorylation; D017670:Sodium Compounds / Q000494:pharmacology*; D008941:Spindle Apparatus / Q000187:drug effects
D018053:Arsenites; C534699:CCNB1 protein, human; D019926:Cyclin B; D056744:Cyclin B1; D017232:Oncogene Proteins v-mos; D017670:Sodium Compounds; C017947:sodium arsenite; D016203:CDC2 Protein Kinase